JMP Securities " Drug Response Rates Significantly Higher Than Competing Drugs" linked.
Fly On The Wall After Hours 8:42 P.M.
May 16, 2013
08:42 EDT HALO Halozyme data favorable, says JMP Securities
JMP Securities was highly encouraged by data from a Phase I trial of Halozyme's PEGPH20 in pancreatic cancer, as the drug generated response rates that were significantly higher than competing drugs,according to the firm. JMP Securities raised its target on Halozyme to $12 from $10 and reiterates an Outperform rating on the shares.